Eli Lilly COVID-19 antibody drug shipments paused over variant concerns

U.S. health officials have paused the distribution of two Eli Lilly & Co. Covid-19 monoclonal antibody treatments because of data showing they aren’t effective against virus variants that are becoming increasingly common across the country.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.